A Novel Mammalian L-ASNase in the treatment of T-ALL
In this study, a research group from Ghent University aims to develop a less toxic an non immunogenic L-ASNase with similar L-ASNase activity as FDA-approved L-ASNase, but without the toxic glutaminase co-activity, for use in the treatment of T-ALL. The result is a novel, mammalian L-ASNase with a high efficacy against T-cell acute lymphoblastic leukemia in vivo. Dr. Maaike Van Trimpont elaborates on the setup of the study.
With the educational support of:
